Literature DB >> 16307332

The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.

Güven Aslan1, Bora Irer, Aykut Kefi, Ilhan Celebi, Kutsal Yörükoğlu, Adil Esen.   

Abstract

OBJECTIVE: The ability of prostate-specific antigen (PSA), free/total PSA and PSA density to predict the pathologic stage in prostate cancer has not been clear yet. In this study, we evaluated the value of PSA subgroups in the prediction of pathologic stage after radical prostatectomy.
METHODS: A total of 42 subjects 55-78-years-old who underwent radical retropubic prostatectomy were included in the study. Preoperative PSA, free/total PSA and PSA density (PSAD) values were compared according to the pathologic stages of radical prostatectomy specimens. Receiver operating characteristics (ROC) curves were measured for each parameter.
RESULTS: The clinical stage that was estimated for all patients was between T1N0M0 and T2bN0M0. Pathologic examination revealed organ-confined disease in 18 patients. The area under curve (AUC) for organ confinement was 0.553 for PSA, 0.446 for free/total PSA ratio and 0.706 for PSAD. Cut-off values providing the best sensitivity and specificity in ROC analysis for PSA, free/total PSA and PSAD were 7.1, 0.15, and 0.17, respectively (likelihood ratio: 0.9, 1 and 2). The positive predictive values at these cut-off values were 0.54, 0.56, and 0.70, respectively. Only PSAD cut-off values was found statistically borderline significant for predicting organ-confined disease.
CONCLUSION: While PSAD is more helpful than PSA and free/total PSA ratio for prediction of organ-confined disease, none of these parameters are significant predictor of pathologic stage for clinically localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307332     DOI: 10.1007/s11255-005-0921-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

Review 1.  The TNM classification of prostate cancer.

Authors:  F H Schröder; P Hermanek; L Denis; W R Fair; M K Gospodarowicz; M Pavone-Macaluso
Journal:  Prostate Suppl       Date:  1992

Review 2.  Prostate-specific antigen: what's new in 1997.

Authors:  J Pannek; A W Partin
Journal:  Oncology (Williston Park)       Date:  1997-09       Impact factor: 2.990

3.  The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.

Authors:  J Noldus; M Graefen; E Huland; C Busch; P Hammerer; H Huland
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

4.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

Authors:  W J Catalona; P C Southwick; K M Slawin; A W Partin; M K Brawer; R C Flanigan; A Patel; J P Richie; P C Walsh; P T Scardino; P H Lange; G H Gasior; K G Loveland; K R Bray
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

5.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.

Authors:  C H Bangma; R Kranse; B G Blijenberg; F H Schröder
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

6.  Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.

Authors:  V Ravery; C Chastang; M Toublanc; L Boccon-Gibod; V Delmas; L Boccon-Gibod
Journal:  Eur Urol       Date:  2000-04       Impact factor: 20.096

7.  Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy.

Authors:  Bertrand Tombal; Michael Querton; Philippe de Nayer; Philippe Sauvage; Jean Pierre Cosyns; Axel Feyaerts; Renier Opsomer; François X Wese; Paul J Van Cangh
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

8.  Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial.

Authors:  J A Smith; P T Scardino; M I Resnick; A D Hernandez; S C Rose; M J Egger
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

9.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

10.  Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.

Authors:  A R Zlotta; B Djavan; M Petein; M Susani; M Marberger; C C Schulman
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

View more
  4 in total

1.  Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.

Authors:  Mohammadreza Nowroozi; Mohsen Ayati; Hassan Jamshidian; Amir Arbab; Hamidreza Ghorbani; Erfan Amini; Hassan Hakima; Sohrab Salehi; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2015-03-20

2.  PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study.

Authors:  Yu-Rong Lin; Xing-Hua Wei; Matthew Uhlman; Xuan-Ting Lin; Si-Feng Wu; Peng-Fei Diao; Hai-Qing Xie; Ke-Ji Xie; Ping Tang
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

4.  Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.

Authors:  Lingyun Xu; Jung-Rok Lee; Shiying Hao; Xuefeng Bruce Ling; James D Brooks; Shan X Wang; Sanjiv Sam Gambhir
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.